Hong Kong Regen Medtech Limited operates Hong Kong’s first and only licensed allogeneic mesenchymal stem cell PIC/S GMP manufacturing facility — advancing regenerative medicine from laboratory to clinic.
Hong Kong Regen Medtech Limited (HKRM) is a clinical-stage stem cell biotechnology company dedicated to developing allogeneic mesenchymal stem cell (MSC) therapies for intractable diseases.
Founded in 2018 and headquartered at Hong Kong Science Park, HKRM acquired proprietary MSC manufacturing technology from Japan in 2020 and has since built Hong Kong’s first and only PIC/S GMP-compliant allogeneic MSC manufacturing facility, receiving its official manufacturing licence from the Hong Kong Department of Health in 2026.
Our pipeline includes an ACLP Phase II clinical programme licensed from a leading Beijing stem cell company in 2025, targeting acute-on-chronic liver failure — a high unmet medical need across Asia.
Our team develops advanced allogeneic MSC manipulation and differentiation platforms that replicate natural developmental microenvironments, producing premium cell therapy products with consistent quality and potency for clinical applications.
As Hong Kong's first and only licensed allogeneic mesenchymal stem cell PIC/S GMP manufacturing facility, we uphold the pharmaceutical industry's most rigorous international standards for cell therapy production and quality assurance.
Strategically positioned at Hong Kong Science Park, HKRM bridges Japan's advanced cell therapy technology with Asia-Pacific's vast patient population, establishing the region's premier regenerative medicine manufacturing hub.
A unique convergence of regulatory achievement, proprietary technology, and strategic market positioning in the rapidly growing Asia-Pacific cell therapy market.
HKRM holds Hong Kong's first and only manufacturing licence for allogeneic MSC cell therapies, creating a significant and defensible regulatory moat in one of Asia's most respected pharmaceutical jurisdictions.
Our MSC manufacturing platform, transferred from Japan in 2020, incorporates proprietary cell manipulation and differentiation protocols that deliver consistent, high-potency allogeneic MSC products at commercial scale.
Our 2025 licensing agreement with a leading Beijing stem cell company provides an ACLP Phase II clinical programme, targeting a high-prevalence, high-mortality condition across Asia with significant unmet medical need.
Our facility meets PIC/S GMP standards — the same rigorous framework adopted by the EU, US FDA, and over 50 regulatory authorities worldwide — enabling future international market access and partnership opportunities.
“To accomplish one’s desire for healthy longevity through stem cell therapies”
We believe in a future where degenerative diseases are no longer inevitable — where science empowers every individual to live longer, healthier lives through the transformative power of regenerative medicine.
We are actively seeking strategic investors, research collaborators, and clinical partners to advance the frontiers of allogeneic MSC cell therapy across Asia-Pacific and beyond.